Hypomethylation of HOXB3 was associated with increased expression in intermediate risk AML patients [30] and plays an important regulatory role, as its over-expression inhibits FLT3-ITD in AML patients carrying that mutation [31]. Here, FLT3 is linked to acute myeloid leukemia.